US Patent Issued to EnGeneIC Molecular Delivery on June 24 for "Encapsulated glycolipid antigens for treatment of neoplastic diseases" (Australian Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,337,033, issued on June 24, was assigned to EnGeneIC Molecular Delivery Pty Ltd (Sydney).

"Encapsulated glycolipid antigens for treatment of neoplastic diseases" was invented by Himanshu Brahmbhatt (Sydney) and Jennifer MacDiarmid (Sydney).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, Alpha-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject...